https://scholars.lib.ntu.edu.tw/handle/123456789/633598
標題: | Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial | 作者: | Chan, A T C Lee, V H F RUEY-LONG HONG Ahn, M-J Chong, W Q Kim, S-B Ho, G F Caguioa, P B Ngamphaiboon, N Ho, C Aziz, M A S A Ng, Q S Yen, C-J Soparattanapaisarn, N Ngan, R K-C Kho, S K Tiambeng, M L A Yun, T Sriuranpong, V Algazi, A P Cheng, A Massarelli, E Swaby, R F Saraf, S Yuan, J Siu, L L |
關鍵字: | immunotherapy; nasopharyngeal cancer; pembrolizumab; programmed death-1 (PD-1) | 公開日期: | 三月-2023 | 卷: | 34 | 期: | 3 | 來源出版物: | Annals of oncology : official journal of the European Society for Medical Oncology | 摘要: | Pembrolizumab previously demonstrated robust antitumor activity and manageable safety in a phase Ib study of patients with heavily pretreated, programmed death ligand 1 (PD-L1)-positive, recurrent or metastatic nasopharyngeal carcinoma (NPC). The phase III KEYNOTE-122 study was conducted to further evaluate pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent and/or metastatic NPC. Final analysis results are presented. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633598 | ISSN: | 09237534 | DOI: | 10.1016/j.annonc.2022.12.007 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。